Trutag Technologies And Spinnaker Biosciences Enters Strategic Partnership For Controlled-Release Drug Delivery

TruTag’s precision nano-porous silica to facilitate Spinnaker’s drug delivery solution

TruTag Technologies, a leader in fabrication of nano-porous silica, product authentication, brand security, and data intelligence solutions, recently announced that it has entered into a strategic partnership with Spinnaker Biosciences, a biotechnology company focused on the development of proprietary technology for controlled/sustained release drug delivery. Under the agreement, TruTag will supply Spinnaker with precision-fabricated nano porous silica particles (pSi).

Founded in 2009, Spinnaker Biosciences is utilizing pSi as a controlled-release drug delivery vehicle. In the Spinnaker solution, active pharmaceutical ingredients are loaded into the nanopores of the silica particles. pSi is an ideal candidate for in-vivo drug delivery due to its inherent biocompatibility, biodegradable nature and precision-fabricated particle porosity, which allows for protected storage and sustained delivery of a therapeutic payload.

The pSi utilized in the Spinnaker solution is highly-customized and has to meet precise porosity and elution specifications. TruTag Technologies has designed and built the world’s most advanced cGMP nano-porous silica manufacturing facility and is unrivalled in its ability to manufacture pSi to precise specifications at a cost and quantity that makes the overall solution viable.

“TruTag Technologies is recognized as the leader in their field and we are excited to be working with their team. TruTag’s ability to reproducibly manufacture large quantities of GMP pSi to our precise specifications has allowed us to focus resources on building our pipeline and expanding the application of our delivery platform,” said Malcolm Finlayson, CEO of Spinnaker Biosciences.

While there are multiple therapeutic areas in which Spinnaker’s pSi can be used, the lead application is in the treatment of neovascular (wet) age-related macular degeneration (ARMD) – a $5+ billion market. The Spinnaker solution offers improved drug delivery to the site of action--the back of the eye--and has a four-month release profile - dramatically improving compliance while reducing the number of injections and the risk of infection.

The initial supply agreement between TruTag and Spinnaker is focused on the provision of pSi in support of Spinnaker’s ARMD clinical program and other third party clinical programs.

“Spinnaker’s drug delivery technology has the potential to be a game-changer that vastly improves therapeutic effectiveness,” said Michael Bartholomeusz, CEO of TruTag Technologies. “We are thrilled to be partnering with Spinnaker as key facilitators of their innovation.”

About TruTag Technologies
TruTag Technologies, Inc. is a leader in precision fabrication of nano-porous silica for drug delivery, product authentication, and data intelligence solutions. The TruTag® platform addresses the $1 trillion global opportunity for sustained release drug therapy, and provides product identity and security solutions to address counterfeit, diverted and adulterated products that impacts the pharmaceutical, life sciences, food, electronics, industrial, and consumer goods industries. TruTag is able to extend the Internet of Things (IoT) to a plethora of new, non-web-connected objects and products with its microscopic ingestible optical memory devices (iOMs), which are made of precision fabricated nano-porous silica that is read using TruTag’s advanced spectral readers. TruTag’s hyperspectral imaging expertise is critical to a broad array of market applications from medical diagnostics to machine vision.

TruTag Technologies has been recognized by the SPIE Prism Awards, the Edison Awards, Fast Company, R&D 100, and was selected a Technology Pioneer by the World Economic Forum as one of the most influential technology companies in the world. For more information, visit www.TruTags.com.